DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy ...
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results